Corrigendum to “Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028”: [ESMO Open 10 (2025) 104295]
M. Donia, H. Jespersen, M. Jalving, R. Lee, H. Eriksson, C. Hoeller, M. Hernberg, I. Gavrilova, L. Kandolf, G. Liszkay, H. Helgadottir, A. Zhukavets, D. Pjanova, I. Marquez-Rodas, B. Neyns, H. Westgeest, I. Pourmir, P. Sobczuk, E. Ellebaek, T. Amaral
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCutaneous Melanoma Detection and Management · Immunotherapy and Immune Responses · Cancer Immunotherapy and Biomarkers